V. M. Prajapati

V. M. Prajapati

Auto-generated profile, based on publicly available information

V. M. Prajapati

CSIR-Central Drug Research Institute

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Microbes and Infection
Verified
Journal Article
Closed access
RKRam Kumar
Ram Kumar
PSPrinci Sharma
Princi Sharma
ACAnu Chauhan
Anu Chauhan
NSNirbhay Singh
Nirbhay Singh
VPV.M. Prajapati
V.M. Prajapati
SSSudheer Kumar Singh
Sudheer Kumar Singh

30 October 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
SYShubhi Yadav
Shubhi Yadav
SDShailesh Dadge
Shailesh Dadge
SRShivam Rathaur
Shivam Rathaur
DMDebalina Maity
Debalina Maity
VPV.M. Prajapati
V.M. Prajapati
JGJiaur R. Gayen
Jiaur R. Gayen

7 October 2026 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
SPShakti Prakash
Shakti Prakash
SKSamprikta Kundu
Samprikta Kundu
ACAyushi Devendrasingh Chaudhary
Ayushi Devendrasingh Chaudhary
SCSakshi Chaudhary
Sakshi Chaudhary
CKChandan Kumar
Chandan Kumar
SGShashi Kumar Gupta
Shashi Kumar Gupta

27 August 2026 in ACS Omega
Verified
Journal Article
Open access
VPV. M. Prajapati
V. M. Prajapati
ACAbhijit Deb Choudhury
Abhijit Deb Choudhury
AKAnuj Kumar
Anuj Kumar
MRManisha Rathore
Manisha Rathore
GSGargi Sharma
Gargi Sharma
SRS. K. Rath
S. K. Rath
Chronic kidney disease (CKD), a heterogeneous disorder with limited therapeutic options, is often complicated by drug-induced nephrotoxicity from aminoglycosides, such as gentamicin (GM). Nintedanib (NTD), a tyrosine kinase inhibitor with antifibrotic and anti-inflammatory properties, holds promise but is limited by poor solubility, low bioavailability, and potential systemic toxicity. To overcome these challenges, a nintedanib nanosuspension polymer (NTD-PNP) was developed using polycaprolactone (PCL) to improve solubility, control drug release, and maximize oral bioavailability. Physicochemical classification confirmed spherical, smooth-surfaced nanoparticles with particle sizes of 106.5–154.7 nm, ζ-potential of −1.39 to +8.86 mV, polydispersity index (PDI) of 0.139–0.384, entrapment efficiency of 28.92–70.92%, and drug loading of 19.94–47.28%. Compared with the free drug, NTD-PNPs displayed superior solubility and prolonged release kinetics. The therapeutic efficacy of NTD-PNPs was evaluated for 28 days in a gentamicin-induced CKD rat model (100 mg/kg, 21 days). Treatment with NTD-PNPs significantly reduced blood urea nitrogen and creatinine levels, indicating improved renal function. Immunohistochemical analysis further revealed downregulation of fibronectin, α-SMA, Smad3, and collagen III expression, and histopathology showed a reduction in tubular degeneration, extracellular matrix accumulation, and fibrosis. Collectively, these findings demonstrate that NTD-PNPs enhance the therapeutic index of nintedanib, offering a promising sustained-release nano formulation to mitigate CKD progression.